13-05-2025
This inhaler not just helps with COPD but is also climate-friendly
A new inhaler that treats chronic obstructive pulmonary disease (COPD) and also helps reduce environmental harm has been approved for use in the UK. This inhaler is already available in Trixeo Aerosphere, known as Breztri Aerosphere in India and other countries, is a triple-combination inhaler used to manage makes this significant is that the latest version of the inhaler is now made using a new type of gas (called a next-generation propellant) that does not contribute much to climate
Specifically, it has "near-zero Global Warming Potential (GWP)", which means it releases almost no greenhouse gases into the atmosphere when used unlike older inhalers, which use gases that are harmful to the change dramatically cuts the device's environmental UK's Medicines and Healthcare Products Regulatory Agency (MHRA) gave approval for this improved version of Trixeo after trials showed that the new propellant works just as well as the older new version uses a compound called HFO-1234ze(E), which has 99.9% lower GWP than the traditional propellants used in most pressurised metered-dose inhalers (pMDIs).Ruud Dobber, Executive Vice President of AstraZeneca's BioPharmaceuticals division, said, 'We're addressing the needs of both patients and the environment. Trixeo with the new propellant is just the start.'This move aligns with growing concerns about climate change and the healthcare sector's role in reducing emissions. Inhalers like pMDIs are widely used across the world. While they are crucial for managing respiratory diseases, their traditional propellants contribute to greenhouse gas emissions. In fact, pMDIs make up 78% of global inhaler use and account for 3% of the NHS's carbon footprint in the metered-dose inhalers are essential for millions living with respiratory diseases. The shift to a low-GWP inhaler means patients don't have to choose between the best treatment and protecting the environment," said Omar Usmani, professor at Imperial College too, has access to this innovation. AstraZeneca Pharma India received approval from the Drugs Controller General of India to import and market Breztri Aerosphere, which has been available in India since January affects over 55 million people in India and is a leading cause of death. Many patients rely on inhalers for daily symptom management. The introduction of a more sustainable inhaler could benefit both public health and the company aims to convert all its pressurised inhalers to this next-gen propellant by 2030 as part of its 'Ambition Zero Carbon' strategy. In the UK, the updated inhaler will begin rolling out in the coming disease control leads to fewer hospital visits and less strain on healthcare systems, ultimately lowering carbon emissions from medical India already having access to this inhaler, it could encourage wider adoption of eco-friendly medicines in the country.
